STOCK TITAN

Masimo to Report Second Quarter 2024 Financial Results After Market Close on Tuesday, August 6

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences earnings

Masimo (NASDAQ: MASI) has announced it will release its second quarter 2024 financial results on Tuesday, August 6, 2024, after the market closes. The results will cover the period ended March 30, 2024. A conference call and webcast to discuss the results will begin at 1:30 p.m. PT (4:30 p.m. ET) on the same day.

The call will be hosted by Joe Kiani, Chairman and CEO, and Micah Young, Executive VP and CFO. Interested parties can register for the call using the provided link to receive dial-in details and a registrant ID. A replay of the webcast and conference call will be available shortly after the conclusion and archived on Masimo's website.

Masimo (NASDAQ: MASI) ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 il martedì 6 agosto 2024, dopo la chiusura del mercato. I risultati copriranno il periodo conclusosi il 30 marzo 2024. Una conferenza telefonica e una trasmissione in diretta per discutere i risultati inizieranno alle 1:30 p.m. PT (4:30 p.m. ET) dello stesso giorno.

La chiamata sarà ospitata da Joe Kiani, Presidente e CEO, e Micah Young, Vicepresidente Esecutivo e CFO. Le parti interessate possono registrarsi per la chiamata utilizzando il link fornito per ricevere i dettagli di accesso e un ID per i registrati. Una registrazione della trasmissione web e della conferenza telefonica sarà disponibile poco dopo la conclusione e archiviata sul sito web di Masimo.

Masimo (NASDAQ: MASI) ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el martes 6 de agosto de 2024, después del cierre del mercado. Los resultados cubrirán el período que finaliza el 30 de marzo de 2024. Una llamada de conferencia y una transmisión en línea para discutir los resultados comenzará a las 1:30 p.m. PT (4:30 p.m. ET) el mismo día.

La llamada será dirigida por Joe Kiani, Presidente y CEO, y Micah Young, Vicepresidente Ejecutivo y CFO. Las partes interesadas pueden registrarse para la llamada utilizando el enlace proporcionado para recibir detalles de marcación y un ID de registrante. Una repetición de la transmisión y de la llamada de conferencia estará disponible poco después de la conclusión y se archivará en el sitio web de Masimo.

Masimo (NASDAQ: MASI)는 2024년 2분기 재무 결과2024년 8월 6일 화요일에 시장 마감 후 발표한다고 밝혔습니다. 결과는 2024년 3월 30일 종료된 기간을 포함합니다. 같은 날 오후 1시 30분 PT (오후 4시 30분 ET)에 결과를 논의하기 위한 회의 전화 및 웹캐스트가 시작될 예정입니다.

이번 전화 회의는 Joe Kiani 회장 겸 CEO와 Micah Young Executive VP 및 CFO가 진행합니다. 관심 있는 당사자는 제공된 링크를 사용하여 전화 회의에 등록하여 다이얼인 세부정보 및 등록자 ID를 받을 수 있습니다. 웹캐스트 및 회의 통화의 재생은 종료 직후 제공되며 Masimo 웹사이트에 아카이브됩니다.

Masimo (NASDAQ: MASI) a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le mardi 6 août 2024, après la clôture du marché. Les résultats couvriront la période se terminant le 30 mars 2024. Une conférence téléphonique et un webinaire pour discuter des résultats commenceront le même jour à 13h30 PT (16h30 ET).

La conférence sera animée par Joe Kiani, Président et CEO, et Micah Young, Vice-président Exécutif et CFO. Les parties intéressées peuvent s'inscrire à l'appel en utilisant le lien fourni pour recevoir les détails de composition et un ID d'enregistrement. Un enregistrement du webinaire et de la conférence téléphonique sera disponible peu après la conclusion et archivé sur le site web de Masimo.

Masimo (NASDAQ: MASI) hat bekannt gegeben, dass die Finanzergebnisse für das zweite Quartal 2024 am Dienstag, den 6. August 2024, nach Börsenschluss veröffentlicht werden. Die Ergebnisse betreffen den Zeitraum bis zum 30. März 2024. Eine Telefonkonferenz und ein Webcast zur Diskussion der Ergebnisse beginnen am selben Tag um 13:30 Uhr PT (16:30 Uhr ET).

Die Konferenz wird von Joe Kiani, Vorstandsvorsitzenden und CEO, sowie Micah Young, Executive VP und CFO, geleitet. Interessierte Parteien können sich über den bereitgestellten Link für die Konferenz anmelden, um Dial-in-Details und eine Teilnehmer-ID zu erhalten. Eine Wiederholung des Webcasts und der Telefonkonferenz wird kurz nach Abschluss verfügbar sein und auf der Website von Masimo archiviert.

Positive
  • None.
Negative
  • None.

Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET)

IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) will release second quarter 2024 financial results for the period ended March 30, 2024, after the market closes on Tuesday, August 6, 2024. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Joe Kiani, Chairman and Chief Executive Officer, and Micah Young, Executive Vice President and Chief Financial Officer.

To register for the conference call and receive the dial-in number, please use the link below. Upon registering, each participant will be provided with details including the dial-in number and a registrant ID number. Reminders about the call will also be sent to registered participants via email.

Conference Call Registration Link (Please register to obtain the dial-in number):

https://registrations.events/direct/Q4I40728531

A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the Company’s website.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio. Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7®, Radius PPG®, and Radius VSM™, portable devices like Rad-67®, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing portfolio of health and wellness solutions includes Radius T°® and the Masimo W1™ watch. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature.

ORi, RPVi, and Radius VSM have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.

Investor Contact:

Eli Kammerman

(949) 297-7077

ekammerman@masimo.com

Media Contact:

Evan Lamb

(949) 297-3376

elamb@masimo.com

Source: Masimo

FAQ

When will Masimo (MASI) release its Q2 2024 financial results?

Masimo (MASI) will release its second quarter 2024 financial results on Tuesday, August 6, 2024, after the market closes.

What period will Masimo's Q2 2024 financial results cover?

Masimo's Q2 2024 financial results will cover the period ended March 30, 2024.

When is Masimo's Q2 2024 earnings conference call scheduled?

Masimo's Q2 2024 earnings conference call is scheduled for Tuesday, August 6, 2024, at 1:30 p.m. PT (4:30 p.m. ET).

Who will host Masimo's Q2 2024 earnings call?

Masimo's Q2 2024 earnings call will be hosted by Joe Kiani, Chairman and CEO, and Micah Young, Executive VP and CFO.

Masimo Corporation

NASDAQ:MASI

MASI Rankings

MASI Latest News

MASI Stock Data

9.12B
49.16M
8.19%
94.77%
6.24%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
IRVINE